AFB Susceptibility MGIT (13 Drugs Panel)
This test evaluates the resistance of Mycobacterium tuberculosis to 13 different drugs. It is essential for guiding treatment in multi-drug resistant tuberculosis.
Overview of AFB Susceptibility MGIT (13 Drugs Panel) in Nagercoil
The AFB Susceptibility MGIT (13 Drugs Panel) is an advanced laboratory test used to determine how Mycobacterium species, including Mycobacterium tuberculosis, respond to a panel of anti-tubercular drugs. Performed using the automated Mycobacteria Growth Indicator Tube (MGIT) system, the test evaluates whether the isolated organism is susceptible or resistant to commonly used first-line and second-line medications. The findings help healthcare providers select the most effective treatment regimen, particularly in cases where drug-resistant tuberculosis is suspected or confirmed.
Who Should Get This Test Done?
This test may be recommended for individuals who:
● Have a confirmed AFB-positive culture requiring drug susceptibility testing.
● Are diagnosed with tuberculosis and need guidance for selecting appropriate anti-tubercular therapy.
● Have persistent or recurrent tuberculosis despite treatment.
● Are suspected of having drug-resistant tuberculosis based on clinical history or previous treatment.
● Require comprehensive susceptibility testing as advised by an infectious disease or pulmonary specialist.
Why Consider This Test?
Not all tuberculosis bacteria respond to the same medicines. In some cases, the bacteria develop resistance, making standard treatment less effective. The AFB Susceptibility MGIT (13 Drugs Panel) helps identify which anti-tubercular drugs are likely to be effective against the isolated organism. This information allows healthcare providers to design a targeted treatment plan, avoid ineffective medications, and improve the overall management of tuberculosis, especially in patients with suspected or confirmed drug-resistant infections.
More Information
The test is performed only after a mycobacterial organism has been successfully isolated in culture. Using the automated MGIT system, it evaluates the organism’s response to a broad range of first-line and second-line anti-tubercular drugs, providing a comprehensive susceptibility profile. The panel includes drugs commonly used in the treatment of tuberculosis and is an important component of laboratory evaluation for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis. The results are interpreted along with clinical findings and other microbiological investigations to guide patient management.
Other Names
● MGIT drug susceptibility test
● TB drug susceptibility test (13 drugs)
● Mycobacterial susceptibility panel
● AFB DST MGIT test
● Second-line TB drug susceptibility test
Test included
- Smear
- Isolate
- Streptomycin 1 Mcg/ml
- Isoniazid 0.1 Mcg/ml
- Rifampicin 1 Mcg/ml
- Ethambutol 5 Mcg/ml
- Pyrazinamide 100 Mcg/ml
- Para-amino Salicylic Acid 4 Mcg/ml
- Ethionamide 5 Mcg/ml
- Kanamycin 2.5 Mcg/ml
- Ofloxacin 2 Mcg/ml
- Capreomycin 2.5 Mcg/ml
- Amikacin 1 Mcg/ml
- Levofloxacin 1.0 Mcg/ml
- Rifabutin 0.5 Mcg/ml
- Linezolid (1 Mcg/ml)
- Clofazimine (1 Mcg/ Ml)
- Moxifloxacin (0.25 Mcg/ml)
- Moxifloxacin (1.0 Mcg/ml)
- Remark
Doctor information
Test code
1464R3
CPT and Loinc codes
Department
- Micro Biology
Turn around time
15 Working Days
Performing locations
5 labs across India
Specimen vol. and vacutainer information
| Specimen | Vacutainer | Volume |
|---|---|---|
| Culture | Others | 1 |
Specimen stability information
Culture
Collection instructions
DRUG LIST MANDATORY REQUIRED
Package price
₹16000
Need Help?
Talk to our health experts for guidance on tests, reports, or bookings.
WhatsApp to Book TestAFB Susceptibility MGIT (13 Drugs Panel)
₹16000